Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial.
BACKGROUND: The IMpassion050 (NCT03726879) primary analysis showed similar pathologic complete response (pCR) rates with/without the addition of neoadjuvant atezolizumab to pertuzumab, trastuzumab, and chemotherapy in high-risk human epidermal growth factor receptor 2-positive early breast cancer in the intention-to-treat and programmed death-ligand 1 (PD-L1)-positive populations. CONCLUSIONS: There were no significant improvements in 3-year EFS (stratified hazard ratio: 0.90; 95% CI: 0.50-1.59) or DFS (unstratified hazard ratio: 0.71; 95% CI: 0.38-1.32) rates with the addition of atezolizumab.
BACKGROUND: The IMpassion050 (NCT03726879) primary analysis showed similar pathologic complete response (pCR) rates with/without the addition of neoadjuvant atezolizumab to pertuzumab, trastuzumab, and chemotherapy in high-risk human epidermal growth factor receptor 2-positive early breast cancer in the intention-to-treat and programmed death-ligand 1 (PD-L1)-positive populations. CONCLUSIONS: There were no significant improvements in 3-year EFS (stratified hazard ratio: 0.90; 95% CI: 0.50-1.59) or DFS (unstratified hazard ratio: 0.71; 95% CI: 0.38-1.32) rates with the addition of atezolizumab.
What the study was
- Study design
- Phase III Clinical Trial
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- ESMO Open
Why it surfaced
Phase III RCT design; Topic: Novel therapeutics immunotherapy CAR-T; Score 7/10 → STANDARD priority
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.